MCID: KRT006
MIFTS: 56

Keratoconjunctivitis

Categories: Eye diseases

Aliases & Classifications for Keratoconjunctivitis

MalaCards integrated aliases for Keratoconjunctivitis:

Name: Keratoconjunctivitis 12 51 41 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9368
ICD10 32 H16.2 H16.20
ICD9CM 34 370.40
MeSH 41 D007637
NCIt 46 C34744
UMLS 69 C0022573

Summaries for Keratoconjunctivitis

MalaCards based summary : Keratoconjunctivitis is related to vernal keratoconjunctivitis and atopic keratoconjunctivitis. An important gene associated with Keratoconjunctivitis is RNASE3 (Ribonuclease A Family Member 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Zinc and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and thyroid, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 72 Keratoconjunctivitis is inflammation (\"-itis\") of the cornea and... more...

Related Diseases for Keratoconjunctivitis

Diseases related to Keratoconjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 379)
# Related Disease Score Top Affiliating Genes
1 vernal keratoconjunctivitis 33.5 CCL11 ICAM1 IL13 IL4 IL5 RNASE3
2 atopic keratoconjunctivitis 33.4 IFNG IL2 IL4 IL5 RNASE3
3 keratoconjunctivitis sicca 33.1 CD79A IL4 NGF TLR9 TNF
4 graft-versus-host disease 30.3 IFNG IL2 TNF
5 papillary conjunctivitis 30.2 CCL11 CXCL8 IL4
6 giant papillary conjunctivitis 30.1 CCL11 CXCL8 IL4
7 uveitis 30.0 ICAM1 IFNG IL4 TNF
8 cellulitis 29.9 IL5 RNASE3 TNF
9 chlamydia 29.6 CD79A CXCL8 IFNG TNF
10 alopecia areata 29.5 ICAM1 IFNG IL2 TNF
11 sleep apnea 29.5 CXCL8 ICAM1 TNF
12 mycobacterium tuberculosis 1 29.4 IFNG IL4 TLR9 TNF
13 lichen planus 29.4 ICAM1 IFNG IL4 TLR9 TNF
14 ocular cicatricial pemphigoid 29.4 CD79A IL4 NGF RNASE3
15 human immunodeficiency virus type 1 29.3 CCL11 IFNG IL2 TNF
16 peritonitis 29.2 CXCL8 ICAM1 IFNG TNF
17 ige responsiveness, atopic 29.2 IFNG IL13 IL4 IL5 RNASE3 TSLP
18 leprosy 3 29.2 CD79A IFNG IL2 IL4 TNF
19 esophagitis 29.0 CCL11 CXCL8 IL13 IL5 TSLP
20 pleurisy 29.0 CXCL8 ICAM1 IFNG IL2 TNF
21 allergic conjunctivitis 29.0 CCL11 CXCL8 ICAM1 IFNG IL13 IL4
22 conjunctivitis 28.9 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
23 colitis 28.9 CXCL8 IFNG IL2 IL4 TLR9 TNF
24 rheumatoid arthritis 28.8 CD79A CXCL8 ICAM1 IFNG IL2 IL4
25 pneumonia 28.8 CCL11 CXCL8 IL13 IL5 TLR9 TNF
26 common variable immunodeficiency 28.8 CD79A IFNG IL2 IL4 TLR9 TNF
27 otitis media 28.7 CCL11 CD79A CXCL8 IL4 RNASE3 TNF
28 autoimmune disease 28.5 CD79A IFNG IL2 IL4 IL5 TLR9
29 dermatitis 28.5 CCL11 CCL17 IFNG IL13 IL4 IL5
30 erythema multiforme 28.4 CCL17 CD79A ICAM1 IFNG IL2 TNF
31 allergic rhinitis 27.7 CCL11 CXCL8 ICAM1 IFNG IL13 IL4
32 rhinitis 27.7 CCL11 CXCL8 ICAM1 IL13 IL4 IL5
33 allergic hypersensitivity disease 27.5 CCL11 CCL17 IFNG IL13 IL4 IL5
34 allergic asthma 27.3 CCL11 CCL17 CXCL8 IFNG IL13 IL4
35 dermatitis, atopic 25.8 CCL11 CCL17 CXCL8 ICAM1 IFNG IL13
36 asthma 25.4 CCL11 CCL17 CD79A CXCL8 ICAM1 IFNG
37 superior limbic keratoconjunctivitis 12.4
38 neurotrophic keratoconjunctivitis 11.9
39 punctate epithelial keratoconjunctivitis 11.9
40 sjogren syndrome 11.8
41 phlyctenulosis 11.7
42 shipyard eye 11.7
43 acute contagious conjunctivitis 11.2
44 exposure keratitis 11.0
45 myelopathy, htlv-1-associated 10.9
46 aplasia of lacrimal and salivary glands 10.9
47 tropical spastic paraparesis 10.9
48 retrovirus-associated myelopathy 10.9
49 mycoplasmal pneumonia 10.6 IFNG IL4
50 loeffler endocarditis 10.6 IL5 RNASE3

Comorbidity relations with Keratoconjunctivitis via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Keratoconjunctivitis:



Diseases related to Keratoconjunctivitis

Symptoms & Phenotypes for Keratoconjunctivitis

MGI Mouse Phenotypes related to Keratoconjunctivitis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.22 IFNG IL5 IL13 AOC1 CCL11 IL2
2 homeostasis/metabolism MP:0005376 10.15 ICAM1 IL4 IFNG IL5 NGF AOC1
3 immune system MP:0005387 10.1 IFNG IL5 IL13 CCL11 IL2 CCL17
4 digestive/alimentary MP:0005381 10.09 IFNG IL5 IL13 IL2 IL4 ICAM1
5 neoplasm MP:0002006 9.73 ICAM1 IL5 IFNG IL2 CD79A TNF
6 no phenotypic analysis MP:0003012 9.7 IL4 IFNG NGF IL13 IL2 CD79A
7 respiratory system MP:0005388 9.56 IL4 IFNG IL5 IL13 CCL11 IL2
8 vision/eye MP:0005391 9.17 ICAM1 IL4 IFNG AOC1 IL2 NGF

Drugs & Therapeutics for Keratoconjunctivitis

Drugs for Keratoconjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 244)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 2 7440-66-6 32051 23994
2
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
3
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 9004-61-9 53477741 24759
4
Glycerol Approved, Investigational Phase 4,Phase 2,Phase 3 56-81-5 753
5
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 299-42-3 9294
6
Iodine Approved, Investigational Phase 4 7553-56-2 807
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
8
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 90-82-4 7028
9
Loteprednol Approved Phase 4,Phase 3,Phase 2 129260-79-3, 82034-46-6 9865442 444025
10
Povidone Approved Phase 4 9003-39-8
11
Ethanol Approved Phase 4 64-17-5 702
12
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
13
Ganciclovir Approved, Investigational Phase 4,Phase 2 82410-32-0 3454
14
Histamine Approved, Investigational Phase 4,Phase 3 51-45-6, 75614-87-8 774
15
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
16
Azithromycin Approved Phase 4 83905-01-5 53477736 447043 55185
17
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
18
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
19
Ofloxacin Approved Phase 4 82419-36-1 4583
20
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
21
Menthol Approved Phase 4 2216-51-5 16666
22
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
23
Dipivefrin Approved Phase 4 52365-63-6 3105
24
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
25
Povidone-iodine Approved Phase 4 25655-41-8
26
Dimenhydrinate Approved Phase 4 523-87-5 441281
27
Sorbitol Approved Phase 4 50-70-4 5780
28
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
29
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
30 Tocopherol Approved, Investigational, Nutraceutical Phase 4
31
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 10883523 5280795 6221
32
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
33 Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4
34
Glutamic Acid Approved, Nutraceutical Phase 4 56-86-0 33032
35
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538
36
Bromfenac Approved July 1997 Phase 4,Phase 3,Phase 2 91714-94-2 60726
37 cadexomer iodine Phase 4
38 Analgesics Phase 4,Phase 3,Phase 2
39 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Retinol palmitate Phase 4
41 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2
42 Micronutrients Phase 4
43 Nasal Decongestants Phase 4,Phase 3,Phase 2,Phase 1
44 Tetrahydrozoline Phase 4,Phase 3,Phase 2,Phase 1
45 Tocopherols Phase 4
46 Tocotrienols Phase 4
47 Trace Elements Phase 4
48 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2
49 Cyclosporins Phase 4,Phase 3,Phase 2,Phase 1
50 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 473)

# Name Status NCT ID Phase Drugs
1 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
2 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
3 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
4 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
5 Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
6 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
7 A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome Unknown status NCT00344721 Phase 4 Essential fatty acid supplement
8 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
9 Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone
10 Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis Completed NCT00357019 Phase 4 N-acetyl-aspartyl-glutamate (NAAXIA Sine)
11 Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Completed NCT01179412 Phase 4 2% povidone-iodine;2% povidone-iodine
12 A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome Completed NCT02139033 Phase 4 Retaine™
13 A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis Completed NCT01533480 Phase 4 Zirgan;genteal gel
14 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
15 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
16 Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Completed NCT00407043 Phase 4 Lotemax;Restasis
17 Comparative Study of Rohto Dry-Aid® and Systane® Ultra in Patients With Dry Eye Completed NCT03183089 Phase 4 Rohto Dry-Aid®;Systane® Ultra
18 Symptom Response in Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra) Completed NCT02985827 Phase 4 Rohto (r) Hydra;Systane (r) Ultra
19 A Study of the Effect of Zinc-Hyaluronate on Ocular Surface Sensations in Patients With Dry Eye Completed NCT02951910 Phase 4
20 Comparison of Autologous Serum Versus Preservative Free Artificial Tear Completed NCT02752763 Phase 4 %40 diluted Autologous serum;Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)
21 A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products (DUNLIN) Completed NCT02014922 Phase 4 TheraTears® Lubricant Eye Drop;TheraTears® preservative-free single-use containers
22 Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Completed NCT01684436 Phase 4
23 Efficacy Study of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints Completed NCT01543061 Phase 4
24 Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops Completed NCT02758327 Phase 4 TheraTears Lubricating Eye Drops
25 Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis® Completed NCT02554981 Phase 4 Cyclosporine 0.05% Ophthalmic Emulsion
26 TearLab Refractive Surgery Dry Eye Study Completed NCT01176045 Phase 4
27 Efficacy of Systane Ultra in Post Menopausal Women With Dry Eye Completed NCT01105910 Phase 4
28 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE) Completed NCT01105624 Phase 4 azithromycin ophthalmic solution, 1%;Visine® for Contacts®
29 Efficacy of Systane Balance to Stabilize the Tear Film in Dry Eye Subjects Completed NCT01086774 Phase 4
30 A Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens Completed NCT01061268 Phase 4 No topical artificial tear;Blink® Tears Lubricant Eye Drops
31 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms Completed NCT00938704 Phase 4 carboxymethylcellulose 0.5% +glycerin 0.9%;sodium hyaluronate 0.18%
32 Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy Completed NCT02121847 Phase 4 cyclosporine 0.05% ophthalmic emulsion;carboxymethylcellulose-based lubricant eye drops
33 Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects Completed NCT01970917 Phase 4
34 Kynex Versus Refresh Plus Study in Subject With Dry Eye Completed NCT00809198 Phase 4
35 A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes Completed NCT00781092 Phase 4
36 Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms Completed NCT00761202 Phase 4 A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®;Sodium hyaluronate
37 Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye Completed NCT00724412 Phase 4
38 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality Completed NCT00622037 Phase 4 PEG-400 based artificial tear;Systane
39 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK). Completed NCT00620893 Phase 4 PEG- 400 based artificial tear;Systane
40 Safety and Efficacy of Optive in Contact Lens Wearers With Dry Eyes Completed NCT00469573 Phase 4 1. Optive
41 Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00405457 Phase 4 Restasis, Optive Tears
42 A Comparison of Optive in Patients Previously Using Systane for the Treatment of Dry Eye Completed NCT00399230 Phase 4 Optive
43 Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00399061 Phase 4 Systane, Optive, Restasis
44 Comparison of Systane Free vs. Saline in the Treatment of Dry Eye Completed NCT00388791 Phase 4 Systane Free
45 Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Completed NCT00386646 Phase 4 0.5% carboxymethylcellulose (CMC) with purite and CMC alone
46 Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Completed NCT00349440 Phase 4 Cyclosporine, Refresh Plus
47 The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients Completed NCT01280110 Phase 4 Hydroxypropylmethylcellulose;Carboxymethylcellulose
48 Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Completed NCT01198782 Phase 4
49 Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery Completed NCT00909324 Phase 4 Pre-LASIK 0.3% hypromellose;Post-LASIK 0.3% hypromellose
50 Systane Clinical Experience Study Completed NCT00818909 Phase 4

Search NIH Clinical Center for Keratoconjunctivitis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: keratoconjunctivitis

Genetic Tests for Keratoconjunctivitis

Anatomical Context for Keratoconjunctivitis

MalaCards organs/tissues related to Keratoconjunctivitis:

38
Eye, Testes, Thyroid, T Cells, Salivary Gland, Bone, Neutrophil

Publications for Keratoconjunctivitis

Articles related to Keratoconjunctivitis:

(show top 50) (show all 1117)
# Title Authors Year
1
Adenovirus-related epidemic keratoconjunctivitis outbreak at a hospital-affiliated ophthalmology clinic. ( 29305276 )
2018
2
Quality of life and clinical characterization of patients with vernal keratoconjunctivitis in a pediatric population in Colombia. ( 29338965 )
2018
3
Topical Tacrolimus 0.03% for Maintenance Therapy in Steroid-Dependent, Recurrent Phlyctenular Keratoconjunctivitis. ( 29309358 )
2018
4
Clinical Severity Classification using Automated Conjunctival Hyperemia Analysis Software in Patients with Superior Limbic Keratoconjunctivitis. ( 29336627 )
2018
5
High Inflammatory Infiltrate Correlates With Poor Symptomatic Improvement After Surgical Treatment for Superior Limbic Keratoconjunctivitis. ( 29346129 )
2018
6
Infectious keratoconjunctivitis in semi-domesticated Eurasian tundra reindeer (Rangifer tarandus tarandus): microbiological study of clinically affected and unaffected animals with special reference to cervid herpesvirus 2. ( 29338721 )
2018
7
Immunohistochemical evaluation of lymphocyte populations in the nictitans glands of normal dogs and dogs with keratoconjunctivitis sicca. ( 29445621 )
2018
8
Vernal keratoconjunctivitis. ( 29391772 )
2018
9
Comparative Evaluation of Tacrolimus Versus Interferon Alpha-2b Eye Drops in the Treatment of Vernal Keratoconjunctivitis: A Randomized, Double-Masked Study. ( 29040120 )
2018
10
Simple methods to optimize the success in microsurgical submandibular gland transplantation for the treatment of patients with keratoconjunctivitis. ( 29451330 )
2018
11
Outcomes and Rationale of Excision and Mucous Membrane Grafting in Palpebral Vernal Keratoconjunctivitis. ( 29040121 )
2018
12
Recombinant type Human mastadenovirus D85 associated with epidemic keratoconjunctivitis since 2015 in Japan. ( 29396992 )
2018
13
Optimising tear replacement rheology in canine keratoconjunctivitis sicca. ( 29303147 )
2018
14
Corneal staining patterns in vernal keratoconjunctivitis: the new VKC-CLEK scoring scale. ( 29367201 )
2018
15
SjAPgren-Like Lacrimal Keratoconjunctivitis in Germ-Free Mice. ( 29438346 )
2018
16
Use of clinical vignette questionnaires to investigate the variation in management of keratoconjunctivitis sicca and acute glaucoma in dogs. ( 29275324 )
2018
17
Successful Subcutaneous Allergen-Specific Immunotherapy in Refractory Atopic Keratoconjunctivitis: A Case Report. ( 29422859 )
2017
18
Topical tacrolimus for the treatment of severe allergic keratoconjunctivitis in children. ( 28954018 )
2017
19
Expression of IL-33 in ocular surface epithelium induces atopic keratoconjunctivitis with activation of group 2 innate lymphoid cells in mice. ( 28855579 )
2017
20
Randomized blinded controlled trial to assess the association between a commercial vaccine against Moraxella bovis and the cumulative incidence of infectious bovine keratoconjunctivitis in beef calves. ( 28703672 )
2017
21
A Case of Type 54 Human Mastadenovirus Keratoconjunctivitis Causing Severe Broad Epithelial Defect Ten Years after LASIK Surgery. ( 28674318 )
2017
22
Sequential Keraring implantation and corneal cross-linking for the treatment of keratoconus in children with vernal keratoconjunctivitis. ( 29123375 )
2017
23
Notes from the Field: Epidemic Keratoconjunctivitis Outbreak Associated with Human Adenovirus Type 8 - U.S. Virgin Islands, June-November 2016. ( 28771460 )
2017
24
Vitamin D levels in children affected by vernal keratoconjunctivitis. ( 27786545 )
2017
25
Kingella kingae Keratitis in a Child with Underlying Vernal Keratoconjunctivitis. ( 28546880 )
2017
26
Outbreaks of epidemic keratoconjunctivitis caused by human adenovirus type 8 in the Tibet Autonomous Region of China in 2016. ( 28915257 )
2017
27
Therapeutic Effect of 0.1% Tacrolimus Eye Drops in the Tarsal Form of Vernal Keratoconjunctivitis. ( 28803239 )
2017
28
Vernal keratoconjunctivitis treated with omalizumab: A case series. ( 28543949 )
2017
29
Microbial community sequencing analysis of the calf eye microbiota and relationship to infectious bovine keratoconjunctivitis. ( 28757034 )
2017
30
Ocular Surface Squamous Neoplasia Associated with Atopic Keratoconjunctivitis. ( 28275599 )
2017
31
Comparative Evaluation of Tacrolimus Versus Interferon Alpha-2b Eye Drops in the Treatment of Vernal Keratoconjunctivitis: A Randomized, Double-Masked Study. ( 28399035 )
2017
32
Tacrolimus eye drops as monotherapy for vernal keratoconjunctivitis: a randomized controlled trial. ( 28832739 )
2017
33
Polyparaneoplastic Manifestations of Malignant Thymoma: A Unique Case of Myasthenia, Autoimmune Hepatitis, Pure Red Cell Aplasia, and Keratoconjunctivitis Sicca. ( 28744421 )
2017
34
Corneal backward scattering and higher-order aberrations in children with vernal keratoconjunctivitis and normal topography. ( 29090512 )
2017
35
Tear ferning in normal dogs and dogs with keratoconjunctivitis sicca. ( 29038779 )
2017
36
Infectious keratoconjunctivitis and occurrence of Mycoplasma conjunctivae and Chlamydiaceae in small domestic ruminants from Central Karakoram, Pakistan. ( 28765500 )
2017
37
Changes in Higher-Order Aberrations After Phototherapeutic Keratectomy for Subepithelial Corneal Infiltrates After Epidemic Keratoconjunctivitis. ( 28742618 )
2017
38
Efficacy and safety of 0.1% lodoxamide for the long-term treatment of superior limbic keratoconjunctivitis. ( 28602013 )
2017
39
Molecular phylogeny of a novel human adenovirus type 8 strain causing a prolonged, multi-state keratoconjunctivitis epidemic in Germany. ( 28084428 )
2017
40
Scleral lenses for severe chronic GvHD-related keratoconjunctivitis sicca: a retrospective study by the SFGM-TC. ( 28218751 )
2017
41
Supratarsal injection of triamcinolone for severe vernal keratoconjunctivitis in children. ( 28832741 )
2017
42
Corneal Complications And Visual Impairment In Vernal Keratoconjunctivitis Patients. ( 28712175 )
2017
43
Acute keratoconjunctivitis due to contamination of contact lens care solution with histamine-producing Raoultella species: A case report. ( 29390396 )
2017
44
Canine oral mucosa evaluation as a potential autograft tissue for the treatment of unresponsive keratoconjunctivitis sicca. ( 28470741 )
2017
45
Comparison between fish and linseed oils administered orally for the treatment of experimentally induced keratoconjunctivitis sicca in rabbits. ( 29038781 )
2017
46
Invasive <em>Neisseria gonorrhoeae</em> producing pre-septal cellulitis and keratoconjunctivitis: diagnosis and management. ( 28899333 )
2017
47
Atopic keratoconjunctivitis complicated by Kocuria koreensis keratitis: the first case. ( 28138334 )
2017
48
Topical Tacrolimus for Corneal Subepithelial Infiltrates Secondary to Adenoviral Keratoconjunctivitis. ( 28704319 )
2017
49
Long-term use of 0.003% tacrolimus suspension for treatment of vernal keratoconjunctivitis. ( 29118487 )
2017
50
Tacrolimus in Corticosteroid-Refractory Vernal Keratoconjunctivitis. ( 27310883 )
2016

Variations for Keratoconjunctivitis

Expression for Keratoconjunctivitis

Search GEO for disease gene expression data for Keratoconjunctivitis.

Pathways for Keratoconjunctivitis

Pathways related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 AOC1 CCL11 CD79A CXCL8 ICAM1 IFNG
2
Show member pathways
13.84 CCL11 CCL17 CXCL8 IL13 IL2 IL4
3
Show member pathways
13.7 CCL11 CCL17 CXCL8 IFNG IL13 IL2
4
Show member pathways
13.59 CCL11 CCL17 CXCL8 ICAM1 IFNG IL13
5
Show member pathways
13.47 CCL11 CCL17 CXCL8 IL13 IL2 IL4
6
Show member pathways
13.41 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
7
Show member pathways
13.36 CCL11 CCL17 CXCL8 IL13 IL2 IL4
8
Show member pathways
13.19 CD79A IFNG IL2 IL4 TLR9 TNF
9 12.88 CXCL8 IFNG IL13 IL2 IL4 IL5
10
Show member pathways
12.88 CXCL8 ICAM1 IFNG IL13 IL2 IL4
11
Show member pathways
12.81 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
12
Show member pathways
12.67 IFNG IL13 IL2 IL4 IL5 TNF
13
Show member pathways
12.66 CD79A IFNG IL2 IL4 TNF
14 12.65 CD79A IFNG IL2 IL4 TLR9 TNF
15
Show member pathways
12.63 CD79A IL13 IL4 IL5 TNF
16
Show member pathways
12.58 CXCL8 IFNG IL2 TLR9 TNF
17
Show member pathways
12.57 ICAM1 IFNG IL2 IL4 TNF
18
Show member pathways
12.49 IFNG IL2 IL4 IL5 TNF
19
Show member pathways
12.47 IFNG IL13 IL2 IL4 IL5 TSLP
20
Show member pathways
12.4 ICAM1 IFNG IL2 IL4 TNF
21
Show member pathways
12.37 CCL11 CCL17 CXCL8 IFNG IL13 IL4
22
Show member pathways
12.3 CCL11 CXCL8 IFNG IL4 TLR9 TNF
23 12.22 CXCL8 IL13 NGF TNF
24
Show member pathways
12.21 CXCL8 IFNG IL13 IL2 IL4 IL5
25 12.11 CXCL8 ICAM1 IFNG IL2 IL4 TNF
26
Show member pathways
12.09 IL13 IL2 IL5 TLR9
27 12.09 CD79A IFNG IL2 IL4 IL5 TNF
28 12.07 CCL11 CXCL8 ICAM1 IL13 IL4 TNF
29
Show member pathways
12 IFNG IL2 TLR9 TNF
30
Show member pathways
11.97 CCL11 CCL17 CXCL8
31
Show member pathways
11.96 IFNG IL2 IL4
32 11.93 CXCL8 ICAM1 IFNG TNF
33 11.9 CXCL8 ICAM1 TNF
34 11.89 IL4 IL5 TNF
35 11.88 CXCL8 IFNG TNF
36 11.87 CXCL8 ICAM1 TNF
37
Show member pathways
11.87 CXCL8 IFNG IL2 IL4 IL5 TNF
38
Show member pathways
11.85 IFNG IL4 TLR9
39 11.84 IFNG IL2 TLR9 TNF
40 11.82 ICAM1 IL4 IL5 TLR9 TNF
41
Show member pathways
11.79 CXCL8 ICAM1 IFNG IL2 TNF
42 11.78 CXCL8 ICAM1 IFNG IL13 IL2 IL4
43 11.77 CCL11 CCL17 IL4 IL5
44 11.75 CCL11 CXCL8 IL13 IL4 IL5 TNF
45 11.7 IFNG IL13 IL2 IL4 IL5 TNF
46
Show member pathways
11.68 IFNG IL2 TNF
47 11.66 CXCL8 ICAM1 IL13 IL4 TNF
48 11.66 CXCL8 ICAM1 IFNG TLR9 TNF
49 11.6 IFNG IL2 TNF
50 11.56 IFNG IL2 TNF

GO Terms for Keratoconjunctivitis

Cellular components related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 AOC1 CCL11 CCL17 CXCL8 IFNG IL13
2 extracellular space GO:0005615 9.47 AOC1 CCL11 CCL17 CXCL8 ICAM1 IFNG
3 external side of plasma membrane GO:0009897 9.46 CD79A ICAM1 IL13 TNF

Biological processes related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.94 CCL17 IL13 IL2 NGF
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.87 CCL11 CCL17 ICAM1 TNF
3 chemotaxis GO:0006935 9.84 CCL11 CCL17 CXCL8 IL4
4 response to ethanol GO:0045471 9.83 ICAM1 IL13 IL2
5 response to virus GO:0009615 9.83 CCL11 IFNG TNF
6 cellular response to interferon-gamma GO:0071346 9.8 CCL11 CCL17 ICAM1
7 inflammatory response GO:0006954 9.8 CCL11 CCL17 CXCL8 IL13 IL5 TLR9
8 movement of cell or subcellular component GO:0006928 9.79 CXCL8 IFNG IL13
9 cellular response to tumor necrosis factor GO:0071356 9.78 CCL11 CCL17 CXCL8 ICAM1
10 chemokine-mediated signaling pathway GO:0070098 9.77 CCL11 CCL17 CXCL8
11 positive regulation of inflammatory response GO:0050729 9.76 IL2 TLR9 TSLP
12 neutrophil chemotaxis GO:0030593 9.75 CCL11 CCL17 CXCL8
13 positive regulation of interleukin-6 production GO:0032755 9.72 TLR9 TNF TSLP
14 positive regulation of nitric oxide biosynthetic process GO:0045429 9.7 ICAM1 IFNG TNF
15 cellular response to interleukin-1 GO:0071347 9.67 CCL11 CCL17 CXCL8 ICAM1
16 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.65 IFNG TNF
17 regulation of regulatory T cell differentiation GO:0045589 9.65 IFNG IL2
18 response to molecule of bacterial origin GO:0002237 9.64 CXCL8 TLR9
19 positive regulation of podosome assembly GO:0071803 9.63 IL5 TNF
20 positive regulation of immunoglobulin secretion GO:0051024 9.63 IL2 IL5
21 negative regulation of endothelial cell apoptotic process GO:2000352 9.63 ICAM1 IL13 IL4
22 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.62 IFNG IL13 IL2 TSLP
23 positive regulation of isotype switching to IgG isotypes GO:0048304 9.61 IL2 IL4
24 positive regulation of interleukin-13 production GO:0032736 9.61 IL4 TSLP
25 immune response GO:0006955 9.61 CCL11 CCL17 CXCL8 IFNG IL13 IL2
26 positive regulation of immunoglobulin production GO:0002639 9.59 IL13 TLR9
27 positive regulation of chemokine production GO:0032722 9.58 TLR9 TNF TSLP
28 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.56 ICAM1 TNF
29 positive regulation of B cell proliferation GO:0030890 9.55 IL13 IL2 IL4 IL5 TLR9
30 negative regulation of complement-dependent cytotoxicity GO:1903660 9.51 IL13 IL4
31 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.49 IFNG TNF
32 positive regulation of vitamin D biosynthetic process GO:0060557 9.43 IFNG TNF
33 regulation of receptor activity GO:0010469 9.36 CCL11 CCL17 CXCL8 IFNG IL13 IL2

Molecular functions related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.33 CCL11 CCL17 CXCL8
2 cytokine activity GO:0005125 9.32 CCL11 CCL17 CXCL8 IFNG IL13 IL2
3 growth factor activity GO:0008083 9.26 IL2 IL4 IL5 NGF

Sources for Keratoconjunctivitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....